Twist Bioscience reported fiscal Q1 revenue of $103.7 million, a 17% year‑over‑year increase driven by growth in DNA synthesis and an emergent AI‑enabled therapeutic discovery business. The company said AI-driven demand produced roughly $25 million in orders in 2025 and shipped 271,000 genes in the quarter. CEO and cofounder Emily Leproust highlighted AI’s role in consolidating volume on Twist’s chips and attracting large pharma, biotech and tech companies expanding into life sciences. The company posted outsized therapeutics revenue growth and signaled continued momentum across DNA synthesis and protein solutions. Investors will watch whether AI‑led demand sustains higher gene volumes and margin expansion.